IRADIMED CORP Files 8-K: Board & Compensation Updates
Ticker: IRMD · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1325618
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing-update
Related Tickers: IRMD
TL;DR
IRADIMED CORP filed an 8-K on Aug 27th covering board changes and exec comp. Watch for updates.
AI Summary
On August 27, 2025, IRADIMED CORP filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes information on Regulation FD disclosures and financial statements, with the report being officially filed on September 2, 2025.
Why It Matters
This filing signals potential shifts in corporate governance and executive incentives at IRADIMED CORP, which could influence strategic direction and investor confidence.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate governance and compensation information, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- IRADIMED CORP (company) — Registrant
- August 27, 2025 (date) — Earliest event reported date
- September 2, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Orlando, Florida (location) — Principal executive offices
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors', but the specific details of these changes are not provided in the excerpt.
What are the key aspects of the compensatory arrangements mentioned?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of these arrangements are not elaborated in the provided text.
What is the significance of the 'Regulation FD Disclosure' item?
This item indicates that the company is making disclosures in compliance with Regulation FD, which aims to ensure fair disclosure of material non-public information to all investors.
When was IRADIMED CORP incorporated?
IRADIMED CORP was incorporated in Delaware, as stated in the filing.
What is the primary business of IRADIMED CORP?
IRADIMED CORP is in the 'SURGICAL & MEDICAL INSTRUMENTS & APPARATUS' industry, with SIC code 3841.
Filing Stats: 845 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2025-09-02 08:00:30
Key Financial Figures
- $0.0001 — h registered: Common stock, par value $0.0001 IRMD NASDAQ Global Market Indicat
Filing Documents
- irmd-20250827x8k.htm (8-K) — 39KB
- irmd-20250827xex99d1.htm (EX-99.1) — 14KB
- irmd-20250827xex99d1001.jpg (GRAPHIC) — 10KB
- 0001558370-25-011834.txt ( ) — 180KB
- irmd-20250827.xsd (EX-101.SCH) — 3KB
- irmd-20250827_lab.xml (EX-101.LAB) — 15KB
- irmd-20250827_pre.xml (EX-101.PRE) — 10KB
- irmd-20250827x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 2, 2025, the Company issued a press release announcing the Board changes described in Item 5.02 of this Current Report on Form 8-K (this " Current Report "). A copy of this press release is furnished with this Current Report as Exhibit 99.1 and incorporated herein by reference. The information in this Item 7.01 and the related information in Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Ac t"), or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated September 2, 2025 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IRADIMED CORPORATION Date: September 2, 2025 By: /s/ John Glenn Name: John Glenn Title: Chief Financial Officer